Polycythemia vera: A concise summary of diagnosis, prognosis, and treatment

Research output: Contribution to journalArticle

Abstract

Polycythemia vera (PV) is currently classified under the chronic myeloid disorders and is subcategorized as a Philadelphia-negative chronic myeloproliferative disorder. Accordingly, it is characterized by trilineage myeloid proliferation and has the propensity to undergo further clonal evolution into myelofibrosis with myeloid metaplasia or acute leukemia. The diagnosis of PV requires the demonstration of an increased hemoglobin concentration or hematocrit from baseline which is associated with a suppressed serum erythropoietin level. These characteristics, along with others, help distinguish PV from secondary causes of erythrocytosis. In addition, bone marrow morphologic and immunohistochemical studies may complement clinical diagnosis. Characteristic clinical features include pruritus, thrombohemorrhagic complications, and erythromelalgic reactions. Advanced age and a previous history of thrombosis are adverse prognostic features. Phlebotomy remains the mainstay of treatment. In addition, high-risk patients may require myelosuppressive agents. The role of aspirin therapy remains undefined.

Original languageEnglish (US)
Pages (from-to)287-292
Number of pages6
JournalCancer Research, Therapy and Control
Volume10
Issue number4
StatePublished - 2000

Fingerprint

Polycythemia Vera
Clonal Evolution
Myeloproliferative Disorders
Polycythemia
Primary Myelofibrosis
Phlebotomy
Pruritus
Erythropoietin
Hematocrit
Aspirin
Leukemia
Hemoglobins
Thrombosis
Therapeutics
Bone Marrow
Serum

Keywords

  • Chronic myeloproliferative disease
  • Myelosuppressive agents
  • Phlebotomy
  • Polycythemia vera

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Polycythemia vera : A concise summary of diagnosis, prognosis, and treatment. / Tefferi, Ayalew.

In: Cancer Research, Therapy and Control, Vol. 10, No. 4, 2000, p. 287-292.

Research output: Contribution to journalArticle

@article{ead30ad4040e4bdab2f69ab0f30e7b40,
title = "Polycythemia vera: A concise summary of diagnosis, prognosis, and treatment",
abstract = "Polycythemia vera (PV) is currently classified under the chronic myeloid disorders and is subcategorized as a Philadelphia-negative chronic myeloproliferative disorder. Accordingly, it is characterized by trilineage myeloid proliferation and has the propensity to undergo further clonal evolution into myelofibrosis with myeloid metaplasia or acute leukemia. The diagnosis of PV requires the demonstration of an increased hemoglobin concentration or hematocrit from baseline which is associated with a suppressed serum erythropoietin level. These characteristics, along with others, help distinguish PV from secondary causes of erythrocytosis. In addition, bone marrow morphologic and immunohistochemical studies may complement clinical diagnosis. Characteristic clinical features include pruritus, thrombohemorrhagic complications, and erythromelalgic reactions. Advanced age and a previous history of thrombosis are adverse prognostic features. Phlebotomy remains the mainstay of treatment. In addition, high-risk patients may require myelosuppressive agents. The role of aspirin therapy remains undefined.",
keywords = "Chronic myeloproliferative disease, Myelosuppressive agents, Phlebotomy, Polycythemia vera",
author = "Ayalew Tefferi",
year = "2000",
language = "English (US)",
volume = "10",
pages = "287--292",
journal = "Cancer Research, Therapy and Control",
issn = "1064-0525",
publisher = "Harwood Academic Publishers",
number = "4",

}

TY - JOUR

T1 - Polycythemia vera

T2 - A concise summary of diagnosis, prognosis, and treatment

AU - Tefferi, Ayalew

PY - 2000

Y1 - 2000

N2 - Polycythemia vera (PV) is currently classified under the chronic myeloid disorders and is subcategorized as a Philadelphia-negative chronic myeloproliferative disorder. Accordingly, it is characterized by trilineage myeloid proliferation and has the propensity to undergo further clonal evolution into myelofibrosis with myeloid metaplasia or acute leukemia. The diagnosis of PV requires the demonstration of an increased hemoglobin concentration or hematocrit from baseline which is associated with a suppressed serum erythropoietin level. These characteristics, along with others, help distinguish PV from secondary causes of erythrocytosis. In addition, bone marrow morphologic and immunohistochemical studies may complement clinical diagnosis. Characteristic clinical features include pruritus, thrombohemorrhagic complications, and erythromelalgic reactions. Advanced age and a previous history of thrombosis are adverse prognostic features. Phlebotomy remains the mainstay of treatment. In addition, high-risk patients may require myelosuppressive agents. The role of aspirin therapy remains undefined.

AB - Polycythemia vera (PV) is currently classified under the chronic myeloid disorders and is subcategorized as a Philadelphia-negative chronic myeloproliferative disorder. Accordingly, it is characterized by trilineage myeloid proliferation and has the propensity to undergo further clonal evolution into myelofibrosis with myeloid metaplasia or acute leukemia. The diagnosis of PV requires the demonstration of an increased hemoglobin concentration or hematocrit from baseline which is associated with a suppressed serum erythropoietin level. These characteristics, along with others, help distinguish PV from secondary causes of erythrocytosis. In addition, bone marrow morphologic and immunohistochemical studies may complement clinical diagnosis. Characteristic clinical features include pruritus, thrombohemorrhagic complications, and erythromelalgic reactions. Advanced age and a previous history of thrombosis are adverse prognostic features. Phlebotomy remains the mainstay of treatment. In addition, high-risk patients may require myelosuppressive agents. The role of aspirin therapy remains undefined.

KW - Chronic myeloproliferative disease

KW - Myelosuppressive agents

KW - Phlebotomy

KW - Polycythemia vera

UR - http://www.scopus.com/inward/record.url?scp=0033825027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033825027&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0033825027

VL - 10

SP - 287

EP - 292

JO - Cancer Research, Therapy and Control

JF - Cancer Research, Therapy and Control

SN - 1064-0525

IS - 4

ER -